Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | NCF1 | P14598 | 1/20 | 0.30 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2356063 | 0.80 | HIF1A (0.42) | HRH1USP2SMN1; SMN2TDP1KDM4E | |
| SCHEMBL238766 | 0.77 | HIF1A (0.39) | HRH1USP2SMN1; SMN2TDP1KDM4E | |
| SCHEMBL3824518 | 0.77 | — | — | |
| SCHEMBL7052608 | 0.77 | HIF1A (0.50) | HRH1USP2SMN1; SMN2TDP1KDM4E | |
| Hydrochloric Acid SCHEMBL28856596 | 0.77 | ALDH1A1 (0.39) | HRH1USP2SMN1; SMN2TDP1KDM4E | |
| SCHEMBL28470549 | 0.77 | HIF1A (0.50) | HRH1USP2SMN1; SMN2TDP1KDM4E | |
| Ethylene SCHEMBL28380221 | 0.74 | HIF1A (0.36) | HRH1USP2SMN1; SMN2TDP1KDM4E | |
| SCHEMBL29001721 | 0.74 | HIF1A (0.46) | HRH1USP2SMN1; SMN2TDP1KDM4E | |
| SCHEMBL2920270 | 0.71 | — | — | |
| SCHEMBL41955 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1925611-B1 | OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-8088796-B2 | Triamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100093785-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090270446-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090239857-A1 | TRIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| US-7109380-B2 | Cyclopentenedione antifungal compounds and methods for their use | THE UNIVERSITY OF MISSISSIPPI (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050215648-A1 | Novel cyclopentenedione antifungal compounds and methods for their use | AGRICULTURE, UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF, THE | 2005-09-29 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270446-A1 | DIAMINE DERIVATIVES | F2, TFPI, F3 | HRH1 1080/4885USP2 3114/4885SMN1; SMN2 4166/4885 |
| US-20050215648-A1 | Novel cyclopentenedione antifungal compounds and methods for their use | CYP51A1, ERG28, CYP4Z1 | HRH1 140/4885USP2 2808/4885SMN1; SMN2 4711/4885 |
| US-20090239857-A1 | TRIAMINE DERIVATIVE | F2, F12, F3 | HRH1 52/4885USP2 4620/4885SMN1; SMN2 3918/4885 |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | F2, PLAT, MPL | HRH1 2476/4885USP2 3806/4885SMN1; SMN2 847/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | HRH1 130/4885USP2 3813/4885SMN1; SMN2 1044/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | HRH1 166/4885USP2 3878/4885SMN1; SMN2 473/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | HRH1 166/4885USP2 3878/4885SMN1; SMN2 473/4885 |
| US-20100093785-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | HRH1 85/4885USP2 4035/4885SMN1; SMN2 666/4885 |
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | C1R, C9, F2 | HRH1 213/4885USP2 2807/4885SMN1; SMN2 847/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | HRH1 166/4885USP2 3878/4885SMN1; SMN2 473/4885 |
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | HRH1 1080/4885USP2 3114/4885SMN1; SMN2 4166/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | HRH1 105/4885USP2 4019/4885SMN1; SMN2 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.